The primary goal of this NCI-funded T32 Cancer Biology Training Grant, CBTG (formally called the Research Oncology Training Grant), is to prepare postdoctoral and predoctoral Trainees for investigative careers in cancer research. The Training Program integrates the training of basic scientists (PhD) and physician scientists (MD/PhD) under the direction of a select faculty from the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University. These faculty mentors bridge traditional departmental boundaries to apply multidisciplinary approaches to fundamental problems in basic cancer biology. The CBTG Training Program provides a forum for training that emphasizes Cancer Research. Since our last competing renewal, we developed a new Cancer Biology Training Program, which trains predoctoral scientists who will advance research on the causes, diagnosis, progression and treatment of experimental and human cancer. To accomplish these training goals, the CBTP has been developed with didactic course work focused on cancer as an interdisciplinary track within the Pathology PhD Program and is jointly sponsored by the Cancer Center and the Department of Pathology. New to this application is a formalized Postdoctoral Program. Postdoctoral Trainees are required to participate in didactic coursework including the Cancer Biology Core Course and the scientific ethics course. We developed an innovative recruiting strategy called the Signaling in Cancer Symposium to attract regional trainees. Furthermore, each postdoctoral trainee is required to constitute a personal Mentoring Committee that meets every six months that is analogous to the thesis committee of predoctoral trainees. The chair of the three person postdoctoral mentoring committee will be a member of the CBTG steering committee and will serve as a """"""""secondary mentor"""""""" for the postdoctoral trainee. Also new to this application is the establishment of Cancer Center Training Scholar positions, providing financial incentives to recruit and retain outstanding postdoctoral fellows who are committed to a cancer research career and whose research progress will be closely monitored by the mentoring committee. All trainees make oral presentations of their research at the monthly Cancer Trainee Seminar Series, which pairs off trainees whose basic research focuses on a particular cancer with an MD Hematology/Oncology Fellow who presents the clinical aspects of that type of cancer. The new seminar was designed to familiarize trainees with the translational aspects of cancer research. The Training Program is governed by a Steering Committee charged with responsibility for (i) active recruitment of trainees, with an emphasis on women and underrepresented minorities;(ii) selection of high caliber candidates who are fully committed to research careers;(iii) tracking the progress of trainees according to specified criteria and standards;(iv) evaluating the mentorship provided by individual faculty;and (v) tracking the success of trainees who have completed the training program.
An abnormally high cancer mortality rate afflicts the 3.9 million people throughout northeast Ohio. Therefore, it is imperative to train and develop the next generation of scientists with a focus on the fundamental problems in basic and translational cancer biology in order to improve cancer patient outcomes in this region and nationally. The Cancer Biology Training Program trains predoctoral and postdoctoral fellows in an NCI-designated Comprehensive Cancer Center at Case Western Reserve University. We request continued funding for years 15-20 of this NCI-supported T32 training grant.
|Barker, Emily C; Kim, Byung-Gyu; Yoon, Ji Hee et al. (2018) Potent suppression of both spontaneous and carcinogen-induced colitis-associated colorectal cancer in mice by dietary celastrol supplementation. Carcinogenesis 39:36-46|
|Reinartz, Roman; Wang, Shanshan; Kebir, Sied et al. (2017) Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma. Clin Cancer Res 23:562-574|
|Samaeekia, Ravand; Adorno-Cruz, Valery; Bockhorn, Jessica et al. (2017) miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. Clin Cancer Res 23:1091-1103|
|Sahni, Jennifer M; Gayle, Sylvia S; Webb, Bryan M et al. (2017) Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors. Cancer Res 77:5395-5408|
|Seachrist, Darcie D; Sizemore, Steven T; Johnson, Emhonta et al. (2017) Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer. Breast Cancer Res 19:66|
|Zhao, Yiqing; Scott, Anthony; Zhang, Peng et al. (2017) Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis. Oncotarget 8:48782-48793|
|Bryson, Benjamin L; Junk, Damian J; Cipriano, Rocky et al. (2017) STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence. Cell Cycle 16:319-334|
|Gayle, Sylvia S; Sahni, Jennifer M; Keri, Ruth A (2017) BETi induction of mitotic catastrophe: towing the LIN9. Oncoscience 4:128-130|
|Junk, D J; Bryson, B L; Smigiel, J M et al. (2017) Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene 36:4001-4013|
|Doherty, Mary R; Smigiel, Jacob M; Junk, Damian J et al. (2016) Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) 8:|
Showing the most recent 10 out of 82 publications